PYCR1 and breast carcinoma: In their in vitro studies, Ding et al. found that inhibition of PYCR1 significantly enhanced the effect of doxorubicin cytotoxicity in breast cancer cell lines MCF-7 (ER positive) and MDA-MB-231 (ER negative).